RxDoctor Payments Data

Andrew Hack, MD

Ophthalmology · Greenville, SCNPI 1770927212

Payments from drug & device makers

$4,234in general payments, 2019–2025

Across 87 payments — averaging $48.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Mallinckrodt Hospital Products Inc.$397
  • Johnson & Johnson Surgical Vision, Inc.$351
  • NEW World Medical,inc.$308
  • AbbVie$198
  • Mallinckrodt Enterprises LLC$189
  • plus $743 from 12 others

What the payments were for

  • Travel & lodging$95523%
  • Food & beverage$3,21776%
  • Education$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,234 in reported general payments places this provider in the 65th percentile of 293 ophthalmology providers in South Carolina.

See all ophthalmology providers in South Carolina

Medicare billing

Part B allowed, 2024
$354,572
Medicare patients
856
Services billed
3,171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj19$612,295
RestasisCyclosporine56$49,804
Prednisolone Acetate765$25,861
Cyclosporine51$19,286
LumiganBimatoprost32$15,042
RocklatanNetarsudil Mesylat/Latanoprost28$14,577
MoxifloxacinMoxifloxacin Hcl445$7,454
ValacyclovirValacyclovir Hcl135$6,450
Loteprednol Etabonate27$5,802
Latanoprost480$3,942
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$3,792
LotemaxLoteprednol Etabonate11$3,723
Travoprost20$3,669
Fluorometholone41$3,430
Brimonidine Tartrate114$1,893

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$72$612,29519 claims
AbbVieRestasis, Lumigan$198$64,84688 claims
Aerie Pharmaceuticals, Inc.Rocklatan$125$14,57728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 293 ophthalmology providers in South Carolina.

Other ophthalmology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →